Abstract:Background: Bronchial asthma (BA) is a heterogeneous disease characterized primarily by chronic airway inflammation and airway hyperresponsiveness (AHR). Objectives: This was a retrospective study aimed at exploring the clinical efficacy of spleen aminopeptide (SA) combined with budesonide (BUD) and levosalbutamol hydrochloride (LEV) as a therapy for pediatric BA, and to observe its effects on inflammatory markers and immune function. Methods: From June 2022 to June 2023, eighty individuals diagnosed with BA were divided into two groups: A control group and an observation group, based on different therapeutic methods. The control group received inhalation therapy with nebulized BUD and LEV, while the observation group received the same inhalation therapy as the control group, along with SA oral lyophilized powder (SAOLP) treatment. A comparative analysis was conducted between the two groups, evaluating clinical efficacy, changes in inflammatory markers and immunological parameters, and adverse drug reactions (ADRs). Results: Upon treatment completion, the observation group exhibited an overall response rate (ORR) of 95.00%, whereas the control group showed an ORR of 80.00% (P < 0.05). Additionally, the observation group had a significantly shorter length of hospital stay (LoHS) and a more rapid improvement in symptoms compared to the control group (both P < 0.05). Following treatment, both groups demonstrated significant decreases in interleukin‐2 (IL‐2), interleukin‐4 (IL‐4), interleukin‐6 (IL‐6), interleukin‐8 (IL‐8), and tumor necrosis factor‐α (TNF‐α) levels (all P < 0.05). However, these reductions were more pronounced in the observation group than in the control group (all P < 0.05). Similarly, after treatment, both groups showed significant increases in T cell subsets CD3+ and CD4+, the CD4+/CD8+ ratio, and levels of immunoglobulin M (IgM), immunoglobulin A (IgA), and immunoglobulin G (IgG) (all P < 0.05), with these changes being more evident in the observation group than in the control group (all P < 0.05). Both groups experienced adverse reactions during the treatment, with an overall adverse reaction rate (OADRR) of 7.50% in the observation group and 10.00% in the control group (χ2 = 0.157, P = 0.692). Conclusions: The combined therapy using SA, BUD, and LEV can significantly improve immune function and reduce inflammatory markers, thereby achieving satisfactory efficacy in treating pediatric BA with a clinically safe profile.

Efficacy and Safety of Montelukast Sodium Tablets Combined with Budesonide Suspension in the Treatment of Patients with Bronchial Asthma

Treatment of Pediatric Mild Persistent Asthma with Low-Dose Budesonide Inhalation Suspension Vs.montelukast in China

Effect of montelukast on the apoptosis of eosinophil in bronchoalveloar lavage fluid

Changes of Eosinophils in Bronchoalveolar Lavage Fluid of Asthma in Children and the Modulation Effect of Montelukast

Clinical Observation of Montelukast Prevention for Wheezing Infants and Young Children after Brochiolitis

The Efficacy of Budesonide-formoterol in Patients with Acute Attacks of Mild-to-moderate Bronchial Asthma: An Observational Study

A Three-Month Non-Interventional Study of Asthma Treatment with Budesonide/Formoterol

The Efficacy of Montelukast on the Airway Hyperresponsiveness in Children with Asthmatic Bron-chitis

Clinical Observation of Meng Lu Montelukast Sodium in the Treatment of Bronchiolitis

Treatment of pediatric mild persistent asthma with low-dose budesonide inhalation suspension vs. montelukast in China

Effects of budesonide combined with salbutamol on pulmonary function and peripheral blood eosinophiles and IgE in patients with acute attack of bronchial asthma

Efficacy and Safety of Budesonide/formoterol Single Inhaler Therapy Versus Budesonide Inhaler Plus Formoterol Inhaler in Asthma Patients

Effects of Budesonide Plus Vitamin AD on Children with Bronchial Asthma and the Effect on Serum IgE and C-reactive Protein

Effect of Huangqi Granules Combined with Budesonide on Clinical Indexes, Clinical Efficacy, and Safety in Children with Bronchial Asthma

A comparative study of efficacy and safety of montelukast versus acebrophylline as add-on therapy to inhaled corticosteroids in bronchial asthma

Budesonide in Combination with Salbutamol in the Treatment of 61 Cases of Childhood Bronchial Asthma During Acute Episodes

A Multicenter, Prospective, Observational Study On Montelukast Monotherapy Or Montelukast-Based Combinations Treating Cough Variant Asthma

Effect of Loratadine and Budesonide on Asthmatic Patients with Allergic Rhinitis

Salbutamol combined with budesonide in treatment of pediatric bronchial asthma and its effect on eosinophils

Clinical Efficacy of Spleen Aminopeptide Combined with Budesonide and Levosalbutamol Hydrochloride, and Its Effects on Inflammatory Markers and Immune Function in Pediatric Bronchial Asthma

[Evaluation of the Clinical Efficacy and the Safety of Salmeterol/fluticasone Propionate Accuhaler Compared to Budesonide Turbuhalar in the Control of Adult Asthma].